Catumaxomab - Neovii Biotech

Drug Profile

Catumaxomab - Neovii Biotech

Alternative Names: Anti-CD3 anti-EpCAM monoclonal antibody; Anti-EpCAM anti-CD3 monoclonal antibody; Removab

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TRION Pharma
  • Developer Neovii Biotech; Swedish Orphan Biovitrum; TRION Pharma
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Market Withdrawal Malignant ascites
  • Discontinued Carcinoma; Gastric cancer; Ovarian cancer

Most Recent Events

  • 25 Sep 2017 Discontinued - Phase-I for Carcinoma in Spain, Denmark and Austria (IV), because not listed on Neovii Biotech's pipeline of September 2017
  • 25 Sep 2017 Discontinued - Phase-II for Gastric cancer (Adjuvant therapy) in Austria, Germany, Spain and United Kingdom (Intraperitoneal), because not listed on Neovii Biotech's pipeline of September 2017
  • 25 Sep 2017 Discontinued - Phase-II for Malignant ascites (Recurrent) in USA (Intraperitoneal), because not listed on Neovii Biotech's pipeline of September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top